Analysts at IMARC expect the global female infertility market to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.76% during 2024-2034.
Analysts at IMARC expect the global female infertility market to reach US$ 2.7 Billion by 2034, exhibiting a growth rate (CAGR) of 2.76% during 2024-2034. The market is driven by numerous innovations in assisted reproductive technologies (ART) such as in vitro fertilization (IVF), preimplantation genetic testing, and oocyte cryopreservation are enhancing treatment success rates and expanding options for patients. In developed regions, like the US, the availability of insurance coverage for fertility treatments further supports market expansion.
Advancements in Assisted Reproductive Technologies (ART): Driving the Female Infertility Market
The rapid advancements in assisted reproductive technologies (ART) are significantly propelling the female infertility market. Innovations such as in vitro fertilization (IVF), intrauterine insemination (IUI), and egg freezing have revolutionized infertility treatment. ART procedures have become increasingly sophisticated, with improved techniques and protocols enhancing success rates and safety. For example, the development of preimplantation genetic testing (PGT) allows for the screening of embryos for genetic abnormalities before implantation, significantly increasing the chances of a healthy pregnancy. The integration of AI and machine learning in ART has also played a pivotal role, aiding in the selection of the most viable embryos, and optimizing treatment protocols. Additionally, the advent of minimally invasive procedures and advanced imaging technologies has reduced the risks and discomfort associated with these treatments, making them more accessible and acceptable to a broader range of patients.
Moreover, the continuous research and development in the field have led to the discovery of novel fertility preservation techniques, such as ovarian tissue cryopreservation, which offers hope to women undergoing treatments that may affect their fertility, such as chemotherapy. The increasing availability of ART services globally, coupled with the growing number of fertility clinics and specialized centers, has further driven the market. A study by Michaela Potančoková et al. projects that the contribution of ART-conceived births to completed fertility in Australia will rise from 2.1% for women born in 1968 to 5.7% for those born in 1986, assuming continued trends in ART success and treatment rates. As more couples become aware of these advanced treatment options and their potential to overcome infertility challenges, the demand for ART procedures is expected to rise. This trend is also supported by favorable government policies and initiatives aimed at promoting reproductive health and providing financial support for infertility treatments.
Request Free Sample Report: https://www.imarcgroup.com/female-infertility-market
Rising Awareness and Acceptance of Infertility Treatments: Contributing to Market Expansion
The increasing awareness and societal acceptance of infertility treatments are major drivers of the female infertility market. Public health campaigns and educational initiatives have played a crucial role in reducing the stigma associated with infertility, encouraging more women to seek medical assistance. Over the years, there has been a marked shift in societal attitudes towards infertility, with greater openness and support for individuals undergoing treatment. This change has been facilitated by the dissemination of information through various channels, including social media, healthcare providers, and patient advocacy groups. These efforts have demystified infertility and its treatments, empowering women with the knowledge to make informed decisions about their reproductive health.
Furthermore, the portrayal of infertility and its treatments in mainstream media has contributed to normalizing the conversation around this topic. Celebrities and public figures sharing their personal experiences with infertility have also played a significant role in raising awareness and reducing the associated stigma. As a result, more women are now willing to explore and pursue treatment options without fear of judgment or discrimination. The growing acceptance is also encouraging insurance companies to provide coverage for infertility treatments, further easing access for patients. This shift in perception has led to higher demand for infertility services, thereby expanding the market.
Additionally, educational initiatives targeted at healthcare professionals have improved the quality of care and support provided to women facing infertility. As per a cross-sectional study by Vinita Singh et al. regarding awareness, knowledge, and the psycho-emotional aspect of infertility among women seeking fertility assistance at a tertiary care hospital in Chhattisgarh, India, 47.7% of women had adequate knowledge about infertility, and 23% experienced significant psychological distress due to infertility. Training programs and continuing education courses ensure that healthcare providers are well-equipped to offer the latest and most effective treatments. The establishment of support groups and counseling services has also created a more supportive environment for women undergoing infertility treatments, addressing their emotional and psychological needs.
Delayed Childbearing and Lifestyle Factors Increasing Infertility Rates
The trend of delayed childbearing, coupled with lifestyle factors, is contributing to rising infertility rates, thereby driving the female infertility market. Many women are choosing to have children later in life due to various reasons, including career aspirations, financial stability, and personal preferences. A study by Kateryna Savelieva et al. found that during the 2010s fertility decline in Finland, Total Fertility Rate (TFR) dropped from 1.87 in 2010 to 1.35 in 2019, with 75% of the decline attributed to the postponement of first births among women under 30. As women age, their fertility naturally declines, leading to an increased incidence of infertility. This demographic shift has created a greater need for infertility treatments and interventions, as more women seek medical assistance to conceive.
Delayed childbearing also increases the risk of age-related conditions such as diminished ovarian reserve and endometriosis, which can further complicate fertility. Lifestyle factors, such as stress, obesity, smoking, and environmental toxins, are exacerbating infertility issues. Modern lifestyles often involve high levels of stress and unhealthy dietary habits, which can negatively impact reproductive health. Obesity, in particular, has been linked to hormonal imbalances and ovulatory dysfunction, making it more challenging for women to conceive. Additionally, exposure to environmental pollutants and endocrine-disrupting chemicals can adversely affect fertility. As these lifestyle factors become more prevalent, the incidence of infertility is expected to rise, driving demand for infertility treatments. The increasing awareness of the impact of lifestyle factors on fertility has led to a growing emphasis on preventive care and lifestyle modifications.
Healthcare providers are now offering comprehensive fertility assessments and personalized treatment plans that address underlying lifestyle issues. This holistic approach not only improves the chances of successful conception but also promotes overall well-being. Moreover, advancements in diagnostic technologies have enabled early detection and intervention for lifestyle-related infertility issues. As more women become aware of the importance of lifestyle factors in reproductive health, the demand for fertility treatments and related services is expected to grow.
However, infertility treatment pricing continues to be a contentious issue that has attracted the attention of Congress. Sen. Elizabeth Warren (D-Mass.), chair of the Senate health committee. She has recently spoken up against the outrageously high prices of most infertility treatment, including Gonal-f and Menopur. Earlier this month, Warren cautioned that the prices of these treatments could make fertility treatments inaccessible for many and exacerbate healthcare inequities.
Leading Companies in the Female Infertility Market:
The market research report by IMARC encompasses a comprehensive analysis of the competitive landscape in the market. Across the global female infertility market, several notable companies are making waves in the industry by offering innovative solutions to address various aspects of women’s health and wellness. While supply issues have stymied the market’s potential, these challenges are increasingly being addressed by pharmaceutical companies. Merck Serono and Ferring Pharmaceuticals, the two of the dominant players, have been investing heavily in their manufacturing capacities in recent months.
Merck pumped US$ 321 Million into its Germany operations, mainly to bolster its supply chain for life sciences and help meet the global demand for its top-selling infertility treatment, Gonal-f. Additionally, Merck KGaA agreed to buy MediCult for $55.1 Million to boost its fertility treatment business, trumping a rival offer.
Ferring Pharmaceuticals, on the other hand, recently announced the successful launch of its third Swiss Franc Bond offering for an amount totaling CHF 330 Million. They offer treatments such as Menopur (Menotropin) and Bravelle (Urofollitropin). Several other drugmakers are also looking to break into the lucrative female infertility treatment space, which is driving the market’s value even higher.
Apart from this, Catalent, Inc., a prominent leader in optimizing product development and full life-cycle supply of better treatments for patients across the globe, and Novo Holdings, a holding and investment company, announced in February 2024 that they have entered into a merger agreement. Novo Holdings has acquired Catalent in an all-cash transaction, thereby valuing Catalent at $16.5 Billion. This merger will allow Catalent to benefit from Novo Holdings’ significant pool of resources to accelerate investment in the business while enhancing key offerings as they continue to provide a comprehensive end-to-end offering of services, premium development as well as excellent manufacturing solutions for pharma and biotech clients.
Ask Our Expert & Browse Full Report with TOC & List of Figure: https://www.imarcgroup.com/female-infertility-market
Regional Analysis:
The major markets for female infertility include the United States. Germany, France, the United Kingdom, Italy, Spain and Japan. According to projections by IMARC, the United States has the largest patient pool for female infertility while also representing the biggest market for its treatment. This can be attributed to the presence of highly advanced healthcare infrastructure with numerous specialized fertility clinics.
Moreover, the growing awareness regarding infertility and improved diagnostic techniques is consequently leading to higher detection rates of infertility issues among women. Additionally, continuous technological advancements in fertility treatments, such as IVF and other ARTs, are significantly improving the overall success rates across the country.
Apart from this, expanding insurance coverage for infertility treatments across the US is also resulting in these services being more accessible to a larger segment of the population. Coupled with supportive government policies and initiatives, this is creating a positive outlook for the US market for infertility treatment worldwide.
Contact US
IMARC Group134 N 4th St. Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Phone Number: - +1 631 791 1145, +91-120-433-0800